Endocrine Testing Market

Executive Summary

Endocrine Testing Market was valued at US $10.54 billion in 2021 and is projected to grow at 8.69% CAGR over the forecast period to reach US $17.38 billion by 2027. Endocrine Testing Market represented US $1.62 billion opportunity over 2019-2021 and estimated to create US $6.84 billion opportunity in 2027 over 2021.

Endocrine Testing from Consainsights analyses the Endocrine Testing Market in the Life Sciences industry over the forecast period to 2027.

Endocrine Testing research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Endocrine Testing segmentation includes Test, Technology, End User and Geography.

Based on the Test, the Endocrine Testing analysis covers Thyroid Test, Insulin Test, Human Chorionic Gonadotropin Test, Prolactin Test, Luteinizing Hormone Test, Progesterone Test, Other Tests.

In Test segment, Thyroid Test segment has highest cagr growth of 7.69%.

Based on the Technology, the Endocrine Testing analysis covers Immunoassay, Tandem Mass Spectroscopy, Sensor Technology, Other Technologies.

In Technology segment, Immunoassay segment has highest cagr growth of 7.69%.

Based on the End User, the Endocrine Testing analysis covers Hospitals, Clincal Laboratories, Other End Users.

In End User segment, Hospitals segment has highest cagr growth of 7.69%.

Based on the region, the Endocrine Testing analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include AB Sciex, Abbott Laboratories, Agilent Technologies Inc., Biomedical Technologies, bioMerieux SA, Bio-Rad Laboratories Inc., Danaher Corporation, DiaSorin SpA, F. Hoffmann-La Roche Ltd, Hologic Inc., Ortho Clinical Diagnostics, Qiagen NV, Quest Diagnostics, Siemens Healthineers AG, Thermo Fisher Scientific and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Test

Introduction

In 2021, Thyroid Test segment has the highest revenue of US $4.15 billion and is expected to grow at CAGR of 7.69% by 2027 Thyroid Test segment has highest cagr growth of 7.69%.

Thyroid Test

Thyroid Test segment was valued at US $3.52 billion in 2019 and is projected to grow at 7.69% CAGR over the forecast period to reach US $6.85 billion by 2027. Thyroid Test segment represented US $0.64 billion opportunity over 2019-2021 and estimated to create US $2.69 billion opportunity in 2027 over 2021.

Insulin Test

Insulin Test segment was valued at US $2.26 billion in 2019 and is projected to grow at 7.69% CAGR over the forecast period to reach US $4.41 billion by 2027. Insulin Test segment represented US $0.41 billion opportunity over 2019-2021 and estimated to create US $1.73 billion opportunity in 2027 over 2021.

Human Chorionic Gonadotropin Test

Human Chorionic Gonadotropin Test segment was valued at US $1.40 billion in 2019 and is projected to grow at 7.69% CAGR over the forecast period to reach US $2.72 billion by 2027. Human Chorionic Gonadotropin Test segment represented US $0.25 billion opportunity over 2019-2021 and estimated to create US $1.07 billion opportunity in 2027 over 2021.

Prolactin Test

Prolactin Test segment was valued at US $0.82 billion in 2019 and is projected to grow at 7.69% CAGR over the forecast period to reach US $1.59 billion by 2027. Prolactin Test segment represented US $0.15 billion opportunity over 2019-2021 and estimated to create US $0.62 billion opportunity in 2027 over 2021.

Luteinizing Hormone Test

Luteinizing Hormone Test segment was valued at US $0.64 billion in 2019 and is projected to grow at 7.69% CAGR over the forecast period to reach US $1.25 billion by 2027. Luteinizing Hormone Test segment represented US $0.12 billion opportunity over 2019-2021 and estimated to create US $0.49 billion opportunity in 2027 over 2021.

Progesterone Test

Progesterone Test segment was valued at US $0.28 billion in 2019 and is projected to grow at 7.69% CAGR over the forecast period to reach US $0.54 billion by 2027. Progesterone Test segment represented US $0.05 billion opportunity over 2019-2021 and estimated to create US $0.21 billion opportunity in 2027 over 2021.

Other Tests

Other Tests segment was valued at US $0.01 billion in 2019 and is projected to grow at 7.69% CAGR over the forecast period to reach US $0.02 billion by 2027. Other Tests segment represented US $0.00 billion opportunity over 2019-2021 and estimated to create US $0.01 billion opportunity in 2027 over 2021.

Technology

Introduction

In 2021, Immunoassay segment has the highest revenue of US $4.81 billion and is expected to grow at CAGR of 7.69% by 2027 Immunoassay segment has highest cagr growth of 7.69%.

Immunoassay

Immunoassay segment was valued at US $4.08 billion in 2019 and is projected to grow at 7.69% CAGR over the forecast period to reach US $7.94 billion by 2027. Immunoassay segment represented US $0.74 billion opportunity over 2019-2021 and estimated to create US $3.12 billion opportunity in 2027 over 2021.

Tandem Mass Spectroscopy

Tandem Mass Spectroscopy segment was valued at US $2.56 billion in 2019 and is projected to grow at 7.69% CAGR over the forecast period to reach US $4.99 billion by 2027. Tandem Mass Spectroscopy segment represented US $0.46 billion opportunity over 2019-2021 and estimated to create US $1.96 billion opportunity in 2027 over 2021.

Sensor Technology

Sensor Technology segment was valued at US $1.55 billion in 2019 and is projected to grow at 7.69% CAGR over the forecast period to reach US $3.02 billion by 2027. Sensor Technology segment represented US $0.28 billion opportunity over 2019-2021 and estimated to create US $1.19 billion opportunity in 2027 over 2021.

Other Technologies

Other Technologies segment was valued at US $0.73 billion in 2019 and is projected to grow at 7.69% CAGR over the forecast period to reach US $1.43 billion by 2027. Other Technologies segment represented US $0.13 billion opportunity over 2019-2021 and estimated to create US $0.56 billion opportunity in 2027 over 2021.

End User

Introduction

In 2021, Hospitals segment has the highest revenue of US $4.91 billion and is expected to grow at CAGR of 7.69% by 2027 Hospitals segment has highest cagr growth of 7.69%.

Hospitals

Hospitals segment was valued at US $4.16 billion in 2019 and is projected to grow at 7.69% CAGR over the forecast period to reach US $8.10 billion by 2027. Hospitals segment represented US $0.75 billion opportunity over 2019-2021 and estimated to create US $3.19 billion opportunity in 2027 over 2021.

Clincal Laboratories

Clincal Laboratories segment was valued at US $2.95 billion in 2019 and is projected to grow at 7.69% CAGR over the forecast period to reach US $5.74 billion by 2027. Clincal Laboratories segment represented US $0.53 billion opportunity over 2019-2021 and estimated to create US $2.26 billion opportunity in 2027 over 2021.

Other End Users

Other End Users segment was valued at US $1.82 billion in 2019 and is projected to grow at 7.69% CAGR over the forecast period to reach US $3.54 billion by 2027. Other End Users segment represented US $0.33 billion opportunity over 2019-2021 and estimated to create US $1.39 billion opportunity in 2027 over 2021.